Carbimazole: Difference between revisions
m Protected "Carbimazole": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 23: | Line 23: | ||
{{SI}} | {{SI}} | ||
__NOTOC__ | __NOTOC__ | ||
'''Carbimazole''' is used to treat [[hyperthyroidism]]. Carbimazole is a pro-drug as after absorption it is converted to the active form, [[methimazole]]. Methimazole prevents the [[peroxidase]] enzyme from coupling and iodinating the tyrosine residues on [[thyroglobulin]], hence reducing the production of the thyroid hormones T3 and T4 ([[thyroxine]]). | '''Carbimazole''' is used to treat [[hyperthyroidism]]. Carbimazole is a pro-drug as after absorption it is converted to the active form, [[methimazole]]. Methimazole prevents the [[peroxidase]] enzyme from coupling and iodinating the tyrosine residues on [[thyroglobulin]], hence reducing the production of the thyroid hormones T3 and T4 ([[thyroxine]]). | ||
| Line 45: | Line 45: | ||
{{Thyroid therapy}} | {{Thyroid therapy}} | ||
[[Category:Antithyroid drugs]] | [[Category:Antithyroid drugs]] | ||
Latest revision as of 23:27, 8 August 2012
 | |
| Clinical data | |
|---|---|
| Routes of administration | oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 85% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C7H10N2O2S |
| Molar mass | 186.233 g/mol |
|
WikiDoc Resources for Carbimazole |
|
Articles |
|---|
|
Most recent articles on Carbimazole Most cited articles on Carbimazole |
|
Media |
|
Powerpoint slides on Carbimazole |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Carbimazole at Clinical Trials.gov Clinical Trials on Carbimazole at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Carbimazole
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Carbimazole Discussion groups on Carbimazole Patient Handouts on Carbimazole Directions to Hospitals Treating Carbimazole Risk calculators and risk factors for Carbimazole
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Carbimazole |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Carbimazole is used to treat hyperthyroidism. Carbimazole is a pro-drug as after absorption it is converted to the active form, methimazole. Methimazole prevents the peroxidase enzyme from coupling and iodinating the tyrosine residues on thyroglobulin, hence reducing the production of the thyroid hormones T3 and T4 (thyroxine).
Clinical use
Therapy for hyperthyroidism generally starts at a high dose of 15 - 40mg continued until the patient has normal thyroid function, and then reduced to a maintenance dose of 5 - 15mg. Treatment is usually given for 12 - 18 months followed by a trial withdraw.
The onset of anti-thyroid effect is rapid but the onset of clinical effects on thyroid hormone levels in the blood is much slower. This is because the large store of pre-formed T3 and T4 in the thyroid gland has to be depleted before any beneficial clinical effect occurs.
Side Effects
Whilst rashes and pruritus are common, these can often be treated with antihistamines without stopping the carbimazole. For those patients where sensitivity reactions can not be controlled, propylthiouracil may be used as an alternative.
Its most serious rare side effect is bone marrow suppression causing neutropenia and agranulocytosis. This may occur at any stage during treatment and without warning. Patients are advised to immediately report symptoms of infection, especially sore throats, so that a full blood count test may be arranged. If this confirms a low neutrophil count then the drug must be discontinued immediately, allowing for usually a prompt recovery. However failure to report suggestive symptoms or delays in considering the possibility of immunosuppresion and its testing, can lead to fatalities.
See also
References
- British National Formulary 45 March 2003
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Antithyroid drugs
- Endocrinology